

Clinical Policy Title:	vimseltinib
Policy Number:	RxA.905
Drug(s) Applied:	Romvimza®
Original Policy Date:	09/10/2025
Last Review Date:	12/11/2025
Line of Business Policy Applies to:	All lines of business (except Medicare)

Criteria

I. Initial Approval Criteria

A. Tenosynovial Giant Cell Tumor (TGCT) (must meet all):

1. Diagnosis of TGCT (also known as giant cell tumor of the tendon sheath [GCT-TS] or pigmented villonodular synovitis [PVNS]);
2. Patient is symptomatic;
3. Surgical resection will potentially cause worsening functional limitations or severe morbidity.

Approval duration

All Lines of Business (except Medicare): 6 months

II. Continued Therapy Approval

A. Tenosynovial Giant Cell Tumor (TGCT) (must meet all):

1. Auto-approval based on lookback functionality within the past 120 days as a proxy for member responding positively to therapy.

Approval duration

All Lines of Business (except Medicare): 12 months

References

1. National Comprehensive Cancer Network. Soft Tissue Sarcoma Version 1.2025. Available at: https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf. Accessed August 12, 2024
2. Romvimza Package Insert. Accessed August 11, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219304s000lbl.pdf
3. Gelderblom H, Vivek Bhadri, Stacchiotti S, et al. Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. Published online June 1, 2024. doi:[https://doi.org/10.1016/s0140-6736\(24\)00885-7](https://doi.org/10.1016/s0140-6736(24)00885-7)

Review/Revision History	Review/Revised Date	P&T Approval Date
Policy established.	09/10/2025	09/10/2025
Policy reviewed	12/11/2025	12/11/2025

This clinical policy has been developed to authorize, modify, or determine coverage for individuals with similar conditions. Specific care and treatment may vary depending on individual need and benefits covered by the plan. This policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. This document may contain prescription brand name drugs that are trademarks of pharmaceutical manufacturers that are not affiliated with RxAdvance.